RespireRx Pharmaceuticals Inc. (RSPI)
OTCQB OTCQB Primary Summary
RSPI Chart
RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury
Glen Rock, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Pink Markets: RSPI) (RespireRx or the Company), focused on the discovery and development of innovative and revolutionary treatments to combat diseases caused by disruption of neuronal signaling, is delighted to announce that the Department of Defense (DOD) has approved a $1.8 million translational research award to Shirley Ryan AbilityLab to fund a two stage Phase 2A and 2B clinical study in order to determine the safety and efficacy of CX1739, its lead clinical AMPAkine, to improve bladder function and motor activity in individuals with spinal cord injury (SCI). This grant award supports the ongoing collaboration among scientist teams led by Milap Sandhu, PT, PhD, research scientist at Shirley Ryan AbilityLab, a rehabilitation research hospital in Chicago, and Dr. Arnold Lippa from RespireRx and Dr. David Fuller from the University of Florida.
RespireRx Pharmaceuticals Inc. Dividends
RespireRx Pharmaceuticals Inc. Earnings
| 13 May 2024 Date | | - Cons. EPS | - EPS |
| 28 Feb 2024 Date | | - Cons. EPS | - EPS |
| 27 Nov 2023 Date | | - Cons. EPS | - EPS |
| 20 Nov 2023 Date | | - Cons. EPS | - EPS |
| 13 Nov 2023 Date | | - Cons. EPS | - EPS |
| 13 May 2024 Date | | - Cons. EPS | - EPS |
| 28 Feb 2024 Date | | - Cons. EPS | - EPS |
| 27 Nov 2023 Date | | - Cons. EPS | - EPS |
| 20 Nov 2023 Date | | - Cons. EPS | - EPS |
| 13 Nov 2023 Date | | - Cons. EPS | - EPS |
RespireRx Pharmaceuticals Inc. (RSPI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has RespireRx Pharmaceuticals Inc. ever had a stock split?
RespireRx Pharmaceuticals Inc. Profile
| Biotechnology Industry | Healthcare Sector | Dr. Arnold S. Lippa Ph.D. CEO | OTCQB Exchange | US7612273059 ISIN |
| US Country | 2 Employees | - Last Dividend | 6 Jan 2021 Last Split | - IPO Date |
Overview
RespireRx Pharmaceuticals Inc., originally known as Cortex Pharmaceuticals, Inc., is a pioneering pharmaceutical company focused on the design, development, and commercialization of innovative treatments for neurological and psychiatric disorders. Since its inception in 1987, the company has been at the forefront of pharmaceutical research, particularly in the realm of cannabinoids and neuromodulators. With its headquarters situated in Glen Rock, New Jersey, RespireRx has dedicated itself to addressing the unmet medical needs in chemotherapy-induced nausea and vomiting, anorexia associated with AIDS, obstructive sleep apnea, opioid-induced respiratory depression, central sleep apnea, and a broad spectrum of CNS-driven neurobehavioral and cognitive disorders.
Products and Services
- ResolutionRx:
- EndeavourRx:
- AMPAkines Program: Includes proprietary compounds known as positive allosteric modulators (PAMs) of glutamate receptors. These compounds are designed to boost neuronal function and show promise in treating a range of conditions, including opioid-induced respiratory depression and central sleep apnea. The lead compound, CX1739, has successfully completed Phase II clinical studies for these applications. The potential of AMPAkines extends into treating CNS-driven neurobehavioral and cognitive disorders, spinal cord injury, neurological diseases, and various orphan indications.
- GABAkines Program: Features proprietary compounds that act as PAMs of GABAA receptors. While specific applications of GABAkines are less detailed, the enhancement of GABAergic signaling is a promising approach for the treatment of neurological disorders and psychiatric conditions where dysregulation of GABA neurotransmission is implicated.
A cutting-edge pharmaceutical cannabinoids platform that features dronabinol, a compound that targets the CB1 and CB2 endocannabinoid receptors. This platform focuses on providing relief for chemotherapy-induced nausea and vomiting, battling anorexia in patients with AIDS, and addressing obstructive sleep apnea. The effectiveness of cannabinoids in these areas opens up new avenues for supportive care in patients undergoing intensive treatments and those suffering from serious health conditions.
A dynamic neuromodulators platform that comprises two significant programs:
In addition to these proprietary programs, RespireRx Pharmaceuticals Inc. is engaged in a research collaboration with University College London to explore the use of AMPAkines for treating GRIA disorders, highlighting its commitment to exploring new therapeutic possibilities.
Contact Information
